JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13

Benzinga Newsdesk www.benzinga.com Neutral 63.5%

Neg 0% Neu 63.5% Pos 0%

JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweight rating and announces Price Target of $13.